SAB Biotherapeutics, Inc.

Clinical trials sponsored by SAB Biotherapeutics, Inc., explained in plain language.

SAB Biotherapeutics, Inc. SABS NASDAQ

Biopharmaceutical company developing antibody therapies using transgenic cattle.

Not investment advice. Company information is shown for context only. Clinical trials frequently fail.

Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.

Trials to join now! 1

New drug could delay type 1 diabetes progression

Disease control Recruiting now

This study tests a new drug called SAB-142 in people recently diagnosed with type 1 diabetes. The goal is to see if it can help the body keep making its own insulin for longer, slowing the disease. About 159 people aged 5 to 40 will receive either the drug or a placebo, and resea…

Phase 2 • Sponsor: SAb Biotherapeutics, Inc. • Aim: Disease control

Last updated Aug 26, 2026 00:00 UTC

SAB Biotherapeutics, Inc.

New drug could delay type 1 diabetes progression